- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02996630
Assessing Neurodevelopment in Congenital Heart Disease. (NEUROHEART)
Abnormal Neurodevelopment Detection in Congenital Heart Disease: Predictive Methods Based on Prenatal and Postnatal Factors.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The main objectives of this study are: 1. to describe the neurodevelopmental outcome of patients with CHD at 24 months of age; 2. identify the subgroup with poorer outcome; and 3. evaluate the utility of fetal and postnatal diagnostic techniques for early detection of patients at risk for altered neurological outcomes.
Seven Spanish referral centers for CHD included in the research network on maternal and child health currently participating in this prospective multicentric case-control coordinated study. Fetuses with CHD (transposition of great arteries, tetralogy of Fallot, hypoplastic left heart syndrome and septal defects) will be studied from 24 weeks of gestation to 2 years of age. Diagnostic tests will be repeated throughout the study in all patients, from the fetal period to 24 months of age, and will include: fetal cerebral hemodynamic Doppler assessment, functional echocardiography, brain MRI, regional cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers analysis. Neurodevelopmental assessment will be made at 12 months of age using the ages and stages questionnaire (ASQ) and at 24 months of age with the Bayley-III test. From this data, statistical analysis will select the most useful as predictors of damage; to be then combined and create algorithms for predicting brain damage and poor neurodevelopment. Once description has been made, we will proceed to identify amongst our results, children with the poorest neurological outcome and remark possible common prenatal and early life markers in them as well as the CHD severity they present.
While advances in early diagnosis and postnatal management have increased survival in CHD children, worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor in the counseling of these pregnancies. Evidence available does not allow clinicians to assess on neurological prognosis although has opened up the possibility of finding prenatal markers of brain damage. Even though, no prospective studies have been performed until now. We present a multicentric prospective study able to recruit enough fetal CHD affected pregnancies to obtain neurological prognostic tools.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Hospital Universitari Vall d'Hebron
-
Contact:
- Irene Ribera, Dr
- Numéro de téléphone: 3086 934893000
- E-mail: irene.ribera@vhir.org
-
Contact:
- Elisa Llurba, Dr
- Numéro de téléphone: 3086 934893000
- E-mail: irene.ribera@vhir.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Single pregnancies
- Major Congenital Heart Disease
- Informed Consent Signed
Exclusion Criteria:
- Major extra-cardiac malformations
- Parental Refusal to participate
- Maternal Chronic Disease
- Multiple Pregnancies
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Healthy fetuses
Pregnant patients carrying a healthy fetus.
Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
|
Fetal Ultrasound exploration
Fetal MRI for brain study
Neurodevelopment paediatric assessment test performed at 2 years of age.
Cord blood samples will be taken after birth in both groups.
|
|
Autre: Congenital Hearth Disease
Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
|
Fetal Ultrasound exploration
Fetal MRI for brain study
Neurodevelopment paediatric assessment test performed at 2 years of age.
Cord blood samples will be taken after birth in both groups.
Congenital Heart Disease repair
EEG and continuous brain oximetry before surgery.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Bailey-III test punctuation
Délai: 45 minutes
|
Results in pediatric Bailey-III test scale
|
45 minutes
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Biparietal diameter (mm)
Délai: one day
|
Biparietal diameter (mm) measured with MRI
|
one day
|
|
Lateral sulcus depth
Délai: one day
|
Lateral sulcus depth (mm) measured with MRI
|
one day
|
|
Cerebral insula
Délai: one day
|
Insula (mm) measured with MRI
|
one day
|
|
Brain biometries
Délai: one day
|
Calcarine sulcus depth (mm)
|
one day
|
|
Cerebral cingulata sulcus
Délai: one day
|
Cingulata sulcus depth (mm) measured with MRI
|
one day
|
|
Corpus callosum
Délai: one day
|
Corpus callosum (mm) measured with MRI
|
one day
|
|
Cerebellum
Délai: one day
|
Cerebellum vermis (mm) measured with MRI
|
one day
|
|
Umbilical doppler
Délai: one day
|
Umbilical artery pulsatility index
|
one day
|
|
Middle cerebral artery doppler
Délai: one day
|
Middle cerebral artery pulsatility index
|
one day
|
|
Angiogenic PLGF (placental growth factor)
Délai: Two days
|
Placental growth factor in maternal serum
|
Two days
|
|
Angiogenic s-FLt (soluble fms-like tyrosine kinase)
Délai: Two days
|
Soluble fms-like tyrosine kinase factor in maternal serum
|
Two days
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Directeur d'études: Elisa Llurba, MD, PhD, Hospital Universitari Vall d'Hebron
Publications et liens utiles
Publications générales
- Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002 Jun 19;39(12):1890-900. doi: 10.1016/s0735-1097(02)01886-7.
- Bellinger DC, Jonas RA, Rappaport LA, Wypij D, Wernovsky G, Kuban KC, Barnes PD, Holmes GL, Hickey PR, Strand RD, et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. N Engl J Med. 1995 Mar 2;332(9):549-55. doi: 10.1056/NEJM199503023320901.
- Limperopoulos C, Majnemer A, Shevell MI, Rosenblatt B, Rohlicek C, Tchervenkov C. Neurodevelopmental status of newborns and infants with congenital heart defects before and after open heart surgery. J Pediatr. 2000 Nov;137(5):638-45. doi: 10.1067/mpd.2000.109152.
- Masoller N, Martinez JM, Gomez O, Bennasar M, Crispi F, Sanz-Cortes M, Egana-Ugrinovic G, Bartrons J, Puerto B, Gratacos E. Evidence of second-trimester changes in head biometry and brain perfusion in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2014 Aug;44(2):182-7. doi: 10.1002/uog.13373. Epub 2014 Jul 8.
- Ruiz A, Cruz-Lemini M, Masoller N, Sanz-Cortes M, Ferrer Q, Ribera I, Martinez JM, Crispi F, Arevalo S, Gomez O, Perez-Hoyos S, Carreras E, Gratacos E, Llurba E. Longitudinal changes in fetal biometry and cerebroplacental hemodynamics in fetuses with congenital heart disease. Ultrasound Obstet Gynecol. 2017 Mar;49(3):379-386. doi: 10.1002/uog.15970.
- Ribera I, Ruiz A, Sanchez O, Eixarch E, Antolin E, Gomez-Montes E, Perez-Cruz M, Cruz-Lemini M, Sanz-Cortes M, Arevalo S, Ferrer Q, Vazquez E, Vega L, Dolader P, Montoliu A, Boix H, Simoes RV, Masoller N, Sanchez-de-Toledo J, Comas M, Bartha JM, Galindo A, Martinez JM, Gomez-Roig L, Crispi F, Gomez O, Carreras E, Cabero L, Gratacos E, Llurba E. Multicenter prospective clinical study to evaluate children short-term neurodevelopmental outcome in congenital heart disease (children NEURO-HEART): study protocol. BMC Pediatr. 2019 Sep 10;19(1):326. doi: 10.1186/s12887-019-1689-y.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PR(AMI)317/2012
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .